

Amebocyte Lysate Market By Type (Limulus Amebocyte Lysate, Tachypleus Amebocyte Lysate) , By Application (Drug Testing, Clinical Diagnosis, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033

<https://marketpublishers.com/r/AFC083640677EN.html>

Date: July 2024

Pages: 280

Price: US\$ 2,655.00 (Single User License)

ID: AFC083640677EN

Abstracts

Amebocyte Lysate Market

The amebocyte lysate market was valued at \$0.6 billion in 2023 and is projected to reach \$1.9 billion by 2033, growing at a CAGR of 11.8% from 2024 to 2033.

Amebocyte lysate, derived from the blood cells or amebocytes of horseshoe crabs, is well-known for its unique property of clotting in the presence of bacterial endotoxins. It is a crucial component in the field of biomedical research & pharmaceuticals and is particularly utilized for the detection of bacterial endotoxins. Due to its exceptional sensitivity, amebocyte lysate is used in environmental monitoring, particularly for the assessment of quality of water and other environmental samples for bacterial contamination.

The field of drug testing is a significant driver of the amebocyte lysate market. Several stages of drug testing such as raw material testing, in-process testing, and final product testing make use of amebocyte lysate and limulus amebocyte lysate (LAL) test for pharmaceutical development. In recent times, recombinant DNA technology is trending for the utilization of properties of amebocyte lysate in different applications. This technology develops copies of the genetic components of amebocyte lysate and offers benefits such as scalability, consistency, & reduced reliance on horseshoe crab populations.

However, compliance with the pharmacopeial regulations established in different countries is a complex and expensive challenge for the market players which prevents the growth of the market. In addition, the ethical considerations regarding the usage of animals in testing and the sustainability of natural resources used in amebocyte lysate production hinder market development. To combat such issues, AmeboGenesis™, a research and discovery organization, introduced a sustainable way of production of amebocytes. This is an innovative method which utilizes a sustainable approach involving the reaping of leg muscles of a horseshoe crab, culturing, and differentiating them into amebocytes by the use of totipotent stem cells. This process ensures a significant control over amebocyte production, along with consistent LAL concentration & production. This approach prevents the annual harvest and bleeding of approximately 800,000 horseshoe crabs, with a notably low survival rate post-harvesting.

Segment Review

The amebocyte lysate market is segmented into type, application, and region. By type, the market is bifurcated into limulus amebocyte lysate and tachypleus amebocyte lysate. On the basis of application, it is divided into drug testing, clinical diagnosis, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the limulus amebocyte lysate segment was the major shareholder in 2023.

Depending on application, the drug testing segment garnered a major share in 2023.

The amebocyte lysate market is expected to experience rapid growth in Asia Pacific by 2033.

Competition Analysis

The major players operating in the global amebocyte lysate market include Lonza Group AG, Charles River Laboratories, Associates Of Cape Cod, Xiamen Bioend Technology, Zhanjiang A&C Biological, GenScript, Nelson Laboratories, LLC, Thermofisher Scientific, Inc., Merck & Co, and Microcoat Biotechnologie GmbH. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their

foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines

Additional company profiles with specific client's interest

Additional country or region analysis- market size and forecast

Expanded list for Company Profiles

Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

Limulus Amebocyte Lysate

Tachypleus Amebocyte Lysate

By Application

Drug Testing

Clinical Diagnosis

Other

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Key Market Players

Lonza Group AG

Charles River Laboratories

Associates of Cape Cod Inc

Xiamen Bioend%li%Technology

Zhanjiang A&C Biological

Genscript Technology Corporation

Nelson Laboratories, LLC

Therm%li%Fisher Scientific, Inc.

Merck & Co., Inc.

Microcoat Biotechnologie GmbH

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
 - 1.4.1. Primary Research
 - 1.4.2. Secondary Research
 - 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings
 - 3.2.1. Top Investment Pockets
 - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
 - 3.3.1. Bargaining Power of Suppliers
 - 3.3.2. Threat of New Entrants
 - 3.3.3. Threat of Substitutes
 - 3.3.4. Competitive Rivalry
 - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
 - 3.4.1. Drivers
 - 3.4.2. Restraints
 - 3.4.3. Opportunities

CHAPTER 4: IBUPROFEN MARKET, BY TYPE

- 4.1. Market Overview
 - 4.1.1 Market Size and Forecast, By Type
- 4.2. Tablet
 - 4.2.1. Key Market Trends, Growth Factors and Opportunities

- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Capsule
 - 4.3.1. Key Market Trends, Growth Factors and Opportunities
 - 4.3.2. Market Size and Forecast, By Region
 - 4.3.3. Market Share Analysis, By Country
- 4.4. Syrup
 - 4.4.1. Key Market Trends, Growth Factors and Opportunities
 - 4.4.2. Market Size and Forecast, By Region
 - 4.4.3. Market Share Analysis, By Country
- 4.5. Injection
 - 4.5.1. Key Market Trends, Growth Factors and Opportunities
 - 4.5.2. Market Size and Forecast, By Region
 - 4.5.3. Market Share Analysis, By Country
- 4.6. Others
 - 4.6.1. Key Market Trends, Growth Factors and Opportunities
 - 4.6.2. Market Size and Forecast, By Region
 - 4.6.3. Market Share Analysis, By Country

CHAPTER 5: IBUPROFEN MARKET, BY APPLICATION

- 5.1. Market Overview
 - 5.1.1 Market Size and Forecast, By Application
- 5.2. Rheumatoid Arthritis And Osteoarthritis
 - 5.2.1. Key Market Trends, Growth Factors and Opportunities
 - 5.2.2. Market Size and Forecast, By Region
 - 5.2.3. Market Share Analysis, By Country
- 5.3. Cancer
 - 5.3.1. Key Market Trends, Growth Factors and Opportunities
 - 5.3.2. Market Size and Forecast, By Region
 - 5.3.3. Market Share Analysis, By Country
- 5.4. Pain/Fever/Dysmenorrhea
 - 5.4.1. Key Market Trends, Growth Factors and Opportunities
 - 5.4.2. Market Size and Forecast, By Region
 - 5.4.3. Market Share Analysis, By Country
- 5.5. Inflammatory Diseases
 - 5.5.1. Key Market Trends, Growth Factors and Opportunities
 - 5.5.2. Market Size and Forecast, By Region
 - 5.5.3. Market Share Analysis, By Country

5.6. Headache

5.6.1. Key Market Trends, Growth Factors and Opportunities

5.6.2. Market Size and Forecast, By Region

5.6.3. Market Share Analysis, By Country

5.7. Others

5.7.1. Key Market Trends, Growth Factors and Opportunities

5.7.2. Market Size and Forecast, By Region

5.7.3. Market Share Analysis, By Country

CHAPTER 6: IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL

6.1. Market Overview

6.1.1 Market Size and Forecast, By Distribution Channel

6.2. Hospital Pharmacies

6.2.1. Key Market Trends, Growth Factors and Opportunities

6.2.2. Market Size and Forecast, By Region

6.2.3. Market Share Analysis, By Country

6.3. Retail Pharmacies

6.3.1. Key Market Trends, Growth Factors and Opportunities

6.3.2. Market Size and Forecast, By Region

6.3.3. Market Share Analysis, By Country

6.4. Online Pharmacies

6.4.1. Key Market Trends, Growth Factors and Opportunities

6.4.2. Market Size and Forecast, By Region

6.4.3. Market Share Analysis, By Country

CHAPTER 7: IBUPROFEN MARKET, BY REGION

7.1. Market Overview

7.1.1 Market Size and Forecast, By Region

7.2. North America

7.2.1. Key Market Trends and Opportunities

7.2.2. Market Size and Forecast, By Type

7.2.3. Market Size and Forecast, By Application

7.2.4. Market Size and Forecast, By Distribution Channel

7.2.5. Market Size and Forecast, By Country

7.2.6. U.S. Ibuprofen Market

7.2.6.1. Market Size and Forecast, By Type

7.2.6.2. Market Size and Forecast, By Application

- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Ibuprofen Market
 - 7.2.7.1. Market Size and Forecast, By Type
 - 7.2.7.2. Market Size and Forecast, By Application
 - 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Ibuprofen Market
 - 7.2.8.1. Market Size and Forecast, By Type
 - 7.2.8.2. Market Size and Forecast, By Application
 - 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
 - 7.3.1. Key Market Trends and Opportunities
 - 7.3.2. Market Size and Forecast, By Type
 - 7.3.3. Market Size and Forecast, By Application
 - 7.3.4. Market Size and Forecast, By Distribution Channel
 - 7.3.5. Market Size and Forecast, By Country
 - 7.3.6. Germany Ibuprofen Market
 - 7.3.6.1. Market Size and Forecast, By Type
 - 7.3.6.2. Market Size and Forecast, By Application
 - 7.3.6.3. Market Size and Forecast, By Distribution Channel
 - 7.3.7. France Ibuprofen Market
 - 7.3.7.1. Market Size and Forecast, By Type
 - 7.3.7.2. Market Size and Forecast, By Application
 - 7.3.7.3. Market Size and Forecast, By Distribution Channel
 - 7.3.8. UK Ibuprofen Market
 - 7.3.8.1. Market Size and Forecast, By Type
 - 7.3.8.2. Market Size and Forecast, By Application
 - 7.3.8.3. Market Size and Forecast, By Distribution Channel
 - 7.3.9. Italy Ibuprofen Market
 - 7.3.9.1. Market Size and Forecast, By Type
 - 7.3.9.2. Market Size and Forecast, By Application
 - 7.3.9.3. Market Size and Forecast, By Distribution Channel
 - 7.3.10. Spain Ibuprofen Market
 - 7.3.10.1. Market Size and Forecast, By Type
 - 7.3.10.2. Market Size and Forecast, By Application
 - 7.3.10.3. Market Size and Forecast, By Distribution Channel
 - 7.3.11. Rest of Europe Ibuprofen Market
 - 7.3.11.1. Market Size and Forecast, By Type
 - 7.3.11.2. Market Size and Forecast, By Application
 - 7.3.11.3. Market Size and Forecast, By Distribution Channel

7.4. Asia-Pacific

7.4.1. Key Market Trends and Opportunities

7.4.2. Market Size and Forecast, By Type

7.4.3. Market Size and Forecast, By Application

7.4.4. Market Size and Forecast, By Distribution Channel

7.4.5. Market Size and Forecast, By Country

7.4.6. Japan Ibuprofen Market

7.4.6.1. Market Size and Forecast, By Type

7.4.6.2. Market Size and Forecast, By Application

7.4.6.3. Market Size and Forecast, By Distribution Channel

7.4.7. China Ibuprofen Market

7.4.7.1. Market Size and Forecast, By Type

7.4.7.2. Market Size and Forecast, By Application

7.4.7.3. Market Size and Forecast, By Distribution Channel

7.4.8. Australia Ibuprofen Market

7.4.8.1. Market Size and Forecast, By Type

7.4.8.2. Market Size and Forecast, By Application

7.4.8.3. Market Size and Forecast, By Distribution Channel

7.4.9. India Ibuprofen Market

7.4.9.1. Market Size and Forecast, By Type

7.4.9.2. Market Size and Forecast, By Application

7.4.9.3. Market Size and Forecast, By Distribution Channel

7.4.10. South Korea Ibuprofen Market

7.4.10.1. Market Size and Forecast, By Type

7.4.10.2. Market Size and Forecast, By Application

7.4.10.3. Market Size and Forecast, By Distribution Channel

7.4.11. Rest of Asia-Pacific Ibuprofen Market

7.4.11.1. Market Size and Forecast, By Type

7.4.11.2. Market Size and Forecast, By Application

7.4.11.3. Market Size and Forecast, By Distribution Channel

7.5. LAMEA

7.5.1. Key Market Trends and Opportunities

7.5.2. Market Size and Forecast, By Type

7.5.3. Market Size and Forecast, By Application

7.5.4. Market Size and Forecast, By Distribution Channel

7.5.5. Market Size and Forecast, By Country

7.5.6. Brazil Ibuprofen Market

7.5.6.1. Market Size and Forecast, By Type

7.5.6.2. Market Size and Forecast, By Application

- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. Saudi Arabia Ibuprofen Market
 - 7.5.7.1. Market Size and Forecast, By Type
 - 7.5.7.2. Market Size and Forecast, By Application
 - 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. South Africa Ibuprofen Market
 - 7.5.8.1. Market Size and Forecast, By Type
 - 7.5.8.2. Market Size and Forecast, By Application
 - 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Ibuprofen Market
 - 7.5.9.1. Market Size and Forecast, By Type
 - 7.5.9.2. Market Size and Forecast, By Application
 - 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

- 9.1. Pfizer Inc.
 - 9.1.1. Company Overview
 - 9.1.2. Key Executives
 - 9.1.3. Company Snapshot
 - 9.1.4. Operating Business Segments
 - 9.1.5. Product Portfolio
 - 9.1.6. Business Performance
 - 9.1.7. Key Strategic Moves and Developments
- 9.2. Abbott Laboratories
 - 9.2.1. Company Overview
 - 9.2.2. Key Executives
 - 9.2.3. Company Snapshot
 - 9.2.4. Operating Business Segments
 - 9.2.5. Product Portfolio

- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Solara Active Pharma Sciences Ltd
 - 9.3.1. Company Overview
 - 9.3.2. Key Executives
 - 9.3.3. Company Snapshot
 - 9.3.4. Operating Business Segments
 - 9.3.5. Product Portfolio
 - 9.3.6. Business Performance
 - 9.3.7. Key Strategic Moves and Developments
- 9.4. BASF SE
 - 9.4.1. Company Overview
 - 9.4.2. Key Executives
 - 9.4.3. Company Snapshot
 - 9.4.4. Operating Business Segments
 - 9.4.5. Product Portfolio
 - 9.4.6. Business Performance
 - 9.4.7. Key Strategic Moves and Developments
- 9.5. Biocause Inc
 - 9.5.1. Company Overview
 - 9.5.2. Key Executives
 - 9.5.3. Company Snapshot
 - 9.5.4. Operating Business Segments
 - 9.5.5. Product Portfolio
 - 9.5.6. Business Performance
 - 9.5.7. Key Strategic Moves and Developments
- 9.6. Shandong Xinhua Pharmaceutical Co Ltd
 - 9.6.1. Company Overview
 - 9.6.2. Key Executives
 - 9.6.3. Company Snapshot
 - 9.6.4. Operating Business Segments
 - 9.6.5. Product Portfolio
 - 9.6.6. Business Performance
 - 9.6.7. Key Strategic Moves and Developments
- 9.7. IOL Chemicals And Pharmaceutical Ltd
 - 9.7.1. Company Overview
 - 9.7.2. Key Executives
 - 9.7.3. Company Snapshot
 - 9.7.4. Operating Business Segments

- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Hubei Biocause Pharmaceutical Co Ltd
 - 9.8.1. Company Overview
 - 9.8.2. Key Executives
 - 9.8.3. Company Snapshot
 - 9.8.4. Operating Business Segments
 - 9.8.5. Product Portfolio
 - 9.8.6. Business Performance
 - 9.8.7. Key Strategic Moves and Developments
- 9.9. Strides Pharma Science Ltd
 - 9.9.1. Company Overview
 - 9.9.2. Key Executives
 - 9.9.3. Company Snapshot
 - 9.9.4. Operating Business Segments
 - 9.9.5. Product Portfolio
 - 9.9.6. Business Performance
 - 9.9.7. Key Strategic Moves and Developments
- 9.10. Perrigo Company Plc
 - 9.10.1. Company Overview
 - 9.10.2. Key Executives
 - 9.10.3. Company Snapshot
 - 9.10.4. Operating Business Segments
 - 9.10.5. Product Portfolio
 - 9.10.6. Business Performance
 - 9.10.7. Key Strategic Moves and Developments

I would like to order

Product name: Amebocyte Lysate Market By Type (Limulus Amebocyte Lysate, Tachypleus Amebocyte Lysate) , By Application (Drug Testing, Clinical Diagnosis, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Product link: <https://marketpublishers.com/r/AFC083640677EN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFC083640677EN.html>